News: Articles and Publications

MAM01 Demonstrates Protection Against Plasmodium falciparum (Pf) Malaria in Humanized Mouse Model 

February 14, 2024•Publication

Immune Correlates of Protection for BCG and M72 TB Vaccines

November 16, 2023•Publication

Safety and immunogenicity of the investigational tuberculosis vaccine M72/AS01E-4 in people living with HIV

November 16, 2023•Publication

A randomized, active-control, open-label phase 2a trial evaluating the bactericidal activity, safety, and pharmacokinetics of TBA-7371 in drug-susceptible pulmonary tuberculosis

November 16, 2023•Publication

Patient Centricity: One BloodDraw at a Time

October 23, 2023•Publication

Implementing a patient-centric sampling strategy in the global clinical development of RSM01 (Anti-RSV mAb)

July 2, 2023•Publication

Calibr and Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Candidate Tuberculosis Treatment Compound

February 15, 2023•Press Release, Written by Gates MRI

Calibr, a division of Scripps Research dedicated to the “bench to bedside” development of transformative medicines, and the Bill & Melinda Gates Medical Research Institute (Gates MRI), today announced a strategic licensing agreement to advance development of a novel investigational compound for tuberculosis treatment.

Immunogenicity Risk Assessment and Integrated Summary of Immunogenicity

December 6, 2022•Publication

Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Candidate Tuberculosis Antibiotics

October 18, 2022•Press Release, Written by Gates MRI

Merck and the Bill & Melinda Gates Medical Research Institute today announced a licensing agreement for two preclinical antibacterial candidates for evaluation as potential components of combination regimens for the treatment of tuberculosis (TB).

Developing Tuberculosis Vaccines for People with HIV: Consensus Statements from an International Expert Panel

October 11, 2022•The Lancet

Gate MRI’s Head of Vaccine Development, Alex Schmidt, joins a panel of international experts on a recent consensus statement for the development of TB vaccines in those with HIV. The paper outlines recommendations for vaccine developers on which vaccines, patient populations, and efficacy endpoints to prioritize when investigating a TB vaccine in individuals with HIV as well as ethical and regulatory factors to consider.

TB Immune Correlates of Protection

September 1, 2022•Publication

PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials

August 17, 2022•Press Release

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) — among Janssen Pharmaceutica NV, Otsuka, TB Alliance and the Bill & Melinda Gates Medical Research Institute — supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development.

What does the future look like for TB care?

August 5, 2022•News Medical

Gates MRI's Head of Therapeutics Development, Charles Wells, gave an interview with News Medical in which he discussed our current research into tuberculosis, the World Health Organization's new guidelines for TB care, and what inspired his career. He also spoke about Gates MRI's novel potential vaccine interventions and how we're supporting future innovative approaches to TB treatment.

Member Spotlight: Q&A with The Bill & Melinda Gates Medical Research Institute

August 1, 2022•MassBio

Gates MRI's CEO Emilio Emini conducted a Q&A with MassBio and shared how Gates MRI is developing biomedical interventions to address global health concerns for those in the greatest need.

Gates MRI Looks to Phase 3 Tuberculosis Vaccine Trial with Epidemiology Study

April 5, 2022•BioPharmaReporter

Gates MRI’s Head of Vaccine Development, Alex Schmidt, discussed Gates MRI’s tuberculosis epidemiology study. He referred to the study’s role in setting the stage for a potential Phase 3 efficacy trial for Gates MRI’s investigational tuberculosis vaccine.